Skip to main content
S&P 5007,743.98+0.28%DOW52,475.10+0.19%NASDAQ26,549.85+0.27%BTC$80,084.00-1.42%ETH$2,323.18-1.53%GOLD$4,039.70-0.29%OIL$101.88-0.88%
Smart Investors Daily
SID Premium
ET

NASDAQ · ETON

Eton Pharmaceuticals, Inc.

Healthcare · Biotechnology

$51.80

Up+$0.64 (+1.25%)

Updated Oct 29, 2026, 11:33 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
453.48M
P/E ratio
-68.06
Dividend yield
0.00%
52-week range
$16.14 – $66.37
Volume
339.66K
Avg. volume
309.26K

Price performance · ETON

ETON price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 28, 2026

ETON closed at $51.80 after 21 trading sessions, up 0.60% for the selected period.

Last close
$51.80
Period change
+0.60%
Period low
$49.22
Period high
$55.62
Daily close
View OHLC price history
ETON OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 28, 2026$50.67$51.97$50.51$51.80339.66K
Oct 27, 2026$50.10$51.42$49.34$51.16340.28K
Oct 26, 2026$50.00$51.33$49.5434$50.17405.28K
Oct 23, 2026$49.89$50.71$48.75$50.00314.77K
Oct 22, 2026$49.36$50.485$48.74$50.02483.69K
Oct 21, 2026$50.93$50.93$48.66$49.30318.99K
Oct 20, 2026$49.36$51.12$48.88$50.19320.55K
Oct 19, 2026$50.29$50.73$48.36$49.22375.9K
Oct 16, 2026$51.35$51.865$49.07$50.31469.03K
Oct 15, 2026$53.275$54.89$51.21$51.33462.32K
Oct 14, 2026$53.50$56.4199$52.66$52.88442.52K
Oct 13, 2026$55.46$55.54$52.72$53.33550.95K
Oct 12, 2026$55.50$57.00$55.20$55.25436.85K
Oct 9, 2026$54.86$56.35$54.2001$55.21371.14K
Oct 8, 2026$54.14$55.47$52.7005$54.75543.38K
Oct 7, 2026$53.84$56.42$53.55$54.88774.68K
Oct 6, 2026$56.15$56.15$54.11$54.77492.35K
Oct 5, 2026$55.85$56.86$54.50$55.62405.46K
Oct 2, 2026$52.42$56.00$52.00$55.36750.08K
Oct 1, 2026$50.18$54.00$49.67$51.981.33M
Sep 30, 2026$59.61$59.66$48.7901$51.491.81M

Latest ETON news

The latest Smart Investors Daily articles mentioning ETON.

Stock researchCompany · Overview

ETON research

Overview

Company profile and research snapshot.

Company profile

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$25.00
Implied upside
—
Analysts
—
ETON recent ratings
DateFirmRatingTarget
Oct 14, 2026HC Wainwright & Co.Buy—
Aug 14, 2026HC Wainwright & Co.Buy—
Aug 14, 2026B. Riley SecuritiesBuy—
Aug 14, 2026Canaccord GenuityBuy—
Aug 11, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Eton Pharmaceuticals (ETON) Stock Still Looks Rich Despite Its New Seizure Drug License

Eton Pharmaceuticals has delivered a very large 3 year gain for shareholders, which naturally raises the question of whether the current share price still lines up with what its earnings can support. With the stock recently closing at US$49.30 after a softer few weeks, the key issue for you is how much of the business’s earnings power is already reflected in that figure. The share price has climbed roughly 13x over the past 3 years. As a result, any misalignment between earnings and...

Yahoo · Sep 28, 2026

Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United StatesEton has integrated full Eton Cares® patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programsCentralized distribution through Anovo Specialty Pharmacy is designed to simplify access and therapy initiation for outpatient prescribing, inpatient consignment, and urgent access coordination DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By